Correction: Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial (J Am Heart Assoc., (2015) 4, e002015, 10.1161/JAHA.115.002015);Blood pressure control and risk of stroke or systemic embolism in patients with atrial fibrillation: Results from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial

Journal of the American Heart Association

Volumn 4, Issue 12, 2015, Pages 1-

  Rao, Meena P ^a   Halvorsen, Sigrun ^b,k   Wojdyla, Daniel ^a   Thomas, Laine ^a   Alexander, John H ^a   Hylek, Elaine M ^c   Hanna, Michael ^d   Cecilia Bahit, M ^e   Lopes, Renato D ^b   De Caterina, Raffaele ^f   Erol, Cetin ^g   Goto, Shinya ^h   Lanas, Fernando ⁱ   Lewis, Basil S ^j   Husted, Steen ^b,k   Gersh, Bernard J ^l   Wallentin, Lars ^m   Granger, Christopher B ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e Grupo Oroño   (Argentina)

^f UNIVERSITY OF CHIETI   (Italy)

^g ANKARA UNIVERSITY   (Turkey)

^h TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ UNIVERSIDAD DE LA FRONTERA   (Chile)

^j TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^k HERNING HOSPITAL   (Denmark)

^l Mayo Clinic College of Medicine   (United States)

^m UPPSALA UNIVERSITY   (Sweden)

more..

Author keywords

Apixaban; Atrial fibrillation; Blood pressure control; Stroke; Systemic embolism

Indexed keywords

APIXABAN; WARFARIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ADULT; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; EMBOLISM; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTOLIC BLOOD PRESSURE; AGED; COMPLICATION; DOUBLE BLIND PROCEDURE; INTRACRANIAL HEMORRHAGES; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME;

AGED; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; DOUBLE-BLIND METHOD; FACTOR XA INHIBITORS; FEMALE; HUMANS; HYPERTENSION; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; PYRAZOLES; PYRIDONES; RISK FACTORS; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 85006189437     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.119.014653     Document Type: Erratum

References (15)

1. Tsang TS, Petty GW, Barnes ME, O'Fallon WM, Bailey KR, Wiebers DO, Sicks JD, Christianson TJ, Seward JB, Gersh BJ. The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades. J Am Coll Cardiol. 2003;42:93-100.
2. Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the Unites States, 1985-1999: implications for primary prevention. Circulation. 2003;108:711-716.
3. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.
4. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
5. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.
6. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263-272.
7. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial fibrillation. JAMA. 2001;285:2864-2870.
8. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risk of stroke and of coronary heart disease. Br Med Bull. 1994;50:272-298.
9. Arima H, Hart RG, Colman S, Chalmers J, Anderson C, Rodgers A, Woodward M, MacMahon S, Neal B. Perinodpril-based blood pressure lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke. 2005;36:2164-2169.
10. Lip GY, Frison L, Grind M. Effect of hypertension on anticoagulated patients with atrial fibrillation. Eur Heart J. 2007;28:752-759.
11. Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke. 2005;36:1588-1593.
12. Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol. 1998;31:1622-1626.
13. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized control trials. Arch Intern Med. 1994;154:1449-1457.
14. Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, Gersh BJ, Granger CB, Hanna M, Horowitz J, Hylek EM, McMurray JJ, Verheugt FW, Wallentin L. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010;159:331-339.
15. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692-694.